Ten drugs in pre-registration likely to be blockbusters by 2025, finds report
New research has found that of the drugs in the pre-registration phase, 10 are expected to become blockbusters over the next six years.
List view / Grid view
New research has found that of the drugs in the pre-registration phase, 10 are expected to become blockbusters over the next six years.
NICE has given its positive opinion to lenalidomide in combination with rituximab as a 'chemotherapy-free' treatment for lymphoma.
Roche has successfully completed its purchase of Promedior, Inc. along with its entire portfolio of fibrotic disease therapeutics.
A new report has revealed Johnson & Johnson as the most valuable pharmaceutical brand, despite a decrease in profits from last year.
A study suggests the global neoantigen cancer vaccine market will grow exponentially due to expected drug launches, new technology reducing costs and currently unmet needs of the market.
Preliminary agenda and speakers announced for LogiPharma, The World’s Leading Pharma Supply Chain Event (21 – 23 April) 2020.
The CMA has cleared the anticipated purchase of gene therapy company Spark Therapeutics by pharmaceutical company Roche Holdings.
Top pharmaceutical companies have reduced their drug costs in China by an average of 61 percent, to be added to the reimbursement list in the country.
Why has the pharma industry and its talents lost interest in developing new antibiotics?
An NHS-wide plan to use more generic and biologic products has reportedly saved the healthcare provider £700 million since 2016.
This August saw nine new green lights from the FDA, all small molecules, which makes up a third of the approvals this year.
The pharmaceutical company Roche has affirmed that it was hit by a Winnti cyber-attack, thought to be supported by the Chinese government.
Chinese government introduces initiative to enable generic drugs to enter market and reduce prices.
The global biobetters market is set to increase due to demand for higher efficacy and safer drugs.
A report has forecasted that the generic oncology drugs market could register an impressive 6 percent CAGR up to the year 2028...